Last reviewed · How we verify
Rituximab window
Rituximab is a chimeric monoclonal antibody that depletes B cells by binding to CD20 antigen, reducing autoimmune and inflammatory responses.
Rituximab is a chimeric monoclonal antibody that depletes B cells by binding to CD20 antigen, reducing autoimmune and inflammatory responses. Used for Rheumatoid arthritis (phase 3 trial context).
At a glance
| Generic name | Rituximab window |
|---|---|
| Sponsor | University Hospital Muenster |
| Drug class | Monoclonal antibody (anti-CD20) |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Rituximab targets CD20, a surface antigen expressed on B lymphocytes, leading to B cell depletion through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). This mechanism reduces the production of autoantibodies and pro-inflammatory cytokines. The 'window' designation likely refers to a specific treatment window or timing protocol in the phase 3 trial design.
Approved indications
- Rheumatoid arthritis (phase 3 trial context)
Common side effects
- Infusion reactions
- Infections
- Cytopenias (neutropenia, thrombocytopenia)
- Fatigue
- Headache
Key clinical trials
- BNHL-2015 for Children or Adolescents in China (PHASE2, PHASE3)
- LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma (EARLY_PHASE1)
- Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study (PHASE4)
- Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma (PHASE2)
- Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma (PHASE2)
- Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis (PHASE2)
- Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma (PHASE2)
- Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rituximab window CI brief — competitive landscape report
- Rituximab window updates RSS · CI watch RSS
- University Hospital Muenster portfolio CI